The Pulmonary Fibrosis Foundation (PFF) announced a research initiative that aims to expand precision medicine strategies for diagnosing and treating idiopathic pulmonary fibrosis (IPF). The study, called PRECISIONS (for Prospective tReatment EffiCacy in IPF uSIng genOtype for Nac Selection), is being funded by a $22 million grant from the National Institutes of Health and …
PFF-supported PRECISIONS Study Aims to Bring Personalized Treatment to IPF
Treatment with the approved therapy Esbriet (pirfenidone), marketed by Genentech, helps preserve lung function in people with idiopathic pulmonary fibrosis (IPF), real-world data from the PROOF registry show. The results were reported in “Longitudinal clinical outcomes in a real-world population of patients with idiopathic…
I am passionate about professional development and ongoing learning opportunities. While I have always thought about these in the context of my education or career, I am looking forward to the learning that will emerge from the PFF Summit 2019 in San Antonio. I will be attending thanks to…
Investigational therapy AD-214 raised no safety concerns in preliminary studies in non-human primates, and AdAlta, the therapy’s developer, is now planning to launch a Phase 1 clinical trial in humans, the company announced. AD-214 is a modification of AdAlta’s original lead candidate for the treatment of pulmonary fibrosis…
Ah, November. Tis the season for declining mental health! The end of fall and beginning of winter always make me anxious. In the past, it was the start of my competitive ski racing season that caused a lot of stress. After that were college midterms. There is no particular…
Activating a dopamine receptor on fibroblast cells (connective tissue cells) may help slow, or even reverse, fibrosis in mice, a study suggests. The study, “Selective YAP/TAZ inhibition in fibroblasts via dopamine receptor D1 agonism reverses fibrosis,” was published in the journal Science Translational Medicine. Fibrosis — abnormal…
Before I got sick, my life was pretty straightforward. I knew what I wanted to study in college, and I earned my bachelor’s and master’s degrees. And although I have struggles in the workplace due to living with idiopathic pulmonary fibrosis (IPF), I am lucky to have a career…
MUC5B genetic variants and shorter telomeres — or chromosome endings — are risk factors associated with greater lung damage and poorer survival in Chinese patients with idiopathic pulmonary fibrosis (IPF), a study has revealed. The study, “The relationship between MUC5B promoter, TERT polymorphisms and telomere…
A genetic variant at the IFNL3 gene is linked to raised levels of IFN-lambda 3 in the blood and is associated with the presence of pulmonary fibrosis in patients with systemic sclerosis, but it does not represent a risk factor for worsening of skin fibrosis in these patients, a…
Managing a chronic illness is not for the faint of heart. Learning to live with idiopathic pulmonary fibrosis (IPF) is the hardest thing I’ve ever done. I applaud my colleagues at Bionews Services and the friends I’ve made around the world who share their stores and advocate for others.
